Acute Coronary Syndrome | Pharmacor | G7 | 2015
Last Updated 16 November 2015
Acute coronary syndrome (ACS)—an umbrella term that encompasses acute ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and unstable angina (UA)—is a leading cause of morbidity and mortality in the developed world. ACS is usually the outcome of atherosclerosis in the coronary arteries with concomitant endothelial dysfunction, followed by plaque disruption and thrombin formation. Despite ongoing improvements in ACS management, rates of reinfarction and death are high, and a pressing need remains for new antithrombotic and antiatherosclerotic therapies that can reduce ischemic complications and mortality in both the acute and the posthospital settings.
Related Market Assessment Reports
Report
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…
Report
Acute Coronary Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – Acute Coronary Syndrome: Secondary Prevention (US)
Acute coronary syndrome (ACS)—a subtype of coronary artery disease—is an umbrella term encompassing ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable…
